New Findings at ASCO22 Underscore Potential of Eisai’s First Antibody-Drug Conjugate
Richard Woodman, MD, Chief Clinical Officer, Oncology Business Group at Eisai, discusses notable presentations on the antibody-drug conjugate co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin (MORAb-202), at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Healthcare. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Healthcare and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Healthcare?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Richard Woodman, M.D., is Chief Clinical Officer (CCLO) for the Oncology Business Group at Eisai Inc. In this role, he has full oversight and responsibility for the strategic and operational leadership of the company’s global oncology clinical development functions, including clinical research, clinical operations, imaging, medical writing, data services, biostatistics and regulatory strategy. He is a member of the company’s global Oncology Executive Leadership team, in addition to serving on the Board of Directors at H3 Biomedicine, the wholly owned precision oncology research and development subsidiary of Eisai.
Dr. Woodman, who has 20 years of pharmaceutical experience in several different functional areas at both large and small biotech organizations, leads the clinical team’s development of Eisai’s next generation oncology products and is accountable for the design of protocols and implementation of all oncology clinical trials. He also oversees all collaboration development projects with partner companies.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
